GPP
AIMT

Great Point Partners’s Aimmune Therapeutics AIMT Stock Holding History

Great Point Partners’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-900,579
Closed -$28.7M – 50
2018
Q1 		$28.7M Buy
900,579
+327,029
+57% +$11.5M 4.26% 12
2017
Q4 		$21.7M Buy
573,550
+73,550
+15% +$2.37M 3.7% 10
2017
Q3 		$12.4M Buy
500,000
+64,598
+15% +$1.39M 2.41% 18
2017
Q2 		$8.95M Buy
435,402
+312,947
+256% +$5.97M 1.6% 22
2017
Q1 		$2.66M Buy
+122,455
New +$2.51M 0.53% 30

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Great Point Partners's AIMT Position: Q2 2018 in Review

Great Point Partners sold out of Aimmune Therapeutics (AIMT) in Q2 2018, closing a stake of 900,579 shares — an estimated $28.7M sold.

Great Point Partners first reported a position in AIMT in Q1 2017 and held it in 5 quarters. The position peaked at $28.7M in Q1 2018. 151 funds tracked by Wall St. Rank hold AIMT as of Q2 2018.

  • Great Point Partners reported no remaining Aimmune Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Great Point Partners sold 900,579 Aimmune Therapeutics shares in Q2 2018, an estimated $28.7M.
  • Great Point Partners first reported a position in Aimmune Therapeutics in Q1 2017 and held it in 5 quarters.
  • Great Point Partners's Aimmune Therapeutics position peaked at $28.7M in Q1 2018.
  • 151 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2018.

Based on Great Point Partners's 13F filing for Q2 2018, filed 14 Aug 2018.